Header
For Healthcare Professionals
dosing

JARDIANCE offers simple, once-daily dosing

keyfact dosing 1
The recommended dose is 10 mg once daily
keyfact dosing 2
Taken with or without food in the morning

No fasting requirements before or after dose

keyfact dosing 3
No dose adjustment of JARDIANCE recommended

When administered with commonly prescribed medications, including RAASi

Can be initiated from eGFR 30 ml/min/1.73 m2 in adults with CKD and may be 
continued until patient requires KRT

Based on dosing recommendations, patients taking JARDIANCE are not required to discontinue therapy for worsening of eGFR or initiation of dialysis

JARDIANCE is not recommended for use to improve glycaemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 ml/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action.

Dosing and Administration

Testing Prior to Initiation of JARDIANCE

  • Assess renal function before initiating JARDIANCE and as clinically indicated [see Warnings and Precautions (5.2)]. 
  • Assess volume status. In patients with volume depletion, correct this condition before initiating JARDIANCE [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].

Recommended Dosage

  • Table 1 presents the recommended dosage of JARDIANCE. 

Indication

Recommended Dosage

Reduce the risk of cardiovascular death and hospitalization in patients with heart failure 

  • 10 mg orally once daily in the morning, taken with or without food. 

Reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression

Reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus with established cardiovascular disease

Glycaemic control in type 2 diabetes mellitus

  • 10 mg orally once daily in the morning, taken with or without food.
  • For additional glycaemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily.

 

CV=cardiovascular; eCVD=established cardiovascular disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; HF=heart failure; hHF=hospitalization for heart failure; T2D=type 2 diabetes; uACR=urinary albumin-to-creatinine ratio.

For more information, please see Prescribing Information.